<DOC>
	<DOCNO>NCT00005999</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient stage IVB recurrent cervical cancer .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Stage IVB Recurrent Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate efficacy arsenic trioxide patient stage IVB recurrent cervical carcinoma . - Determine safety treatment patient . OUTLINE : Patients receive arsenic trioxide IV 1-4 hour day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 12-37 patient accrue study 10-19 month .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IVB recurrent cervical carcinoma amenable standard curative therapy Squamous carcinoma OR Adenocarcinoma Measurable disease At least 20 mm conventional technique OR At least 10 mm spiral CT scan Nonmeasurable disease define follow : Bone disease Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion No active brain metastasis PATIENT CHARACTERISTICS : Age : 17 Performance status : Karnofsky 60100 % Life expectancy : Greater 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No cardiac arrhythmia , unstable angina , conduction abnormality No New York Heart Association class III IV heart disease clinical evidence congestive heart failure Pretreatment QTc le 500 msec Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 month study No grade 3 great neurologic abnormality No history seizures No concurrent uncontrolled active infection PRIOR CONCURRENT THERAPY : Biologic therapy : No 2 prior therapy advance disease Chemotherapy : No 2 prior therapy advance disease At least 4 week since prior chemotherapy Endocrine therapy : No 2 prior therapy advance disease Radiotherapy : No 2 prior therapy advance disease At least 4 week since prior radiotherapy Surgery : Not specify Other : At least 4 week since prior cytotoxic therapy investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2002</verification_date>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
</DOC>